UNSPSC 51111901: Asparaginase

This classification denotes a natural antineoplastic product hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1. with the molecular formula C1377H2208N382O442S17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G4FQ3CKY5R, chemically known as E. coli L-asparagine amidohydrolase but generally known as asparaginase. European Medicines Agency schedules asparaginase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12950MIG.

World Health Organization schedules asparaginase in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, ASPARAGINASE remains the US FDA Preferred Term for this commodity.

UNSPSC 51111901 Asparaginase, a Commodity code, covers the procurement of this injectable chemotherapy agent used primarily in acute lymphoblastic leukemia (ALL) treatment protocols. State and local governments purchase asparaginase through health departments, public hospital systems, and cancer treatment centers to support inpatient and outpatient oncology programs. The drug is procured as a therapeutic pharmaceutical in both branded and generic formulations, often through competitive bidding processes that emphasize price, supply reliability, and manufacturer certifications.

The recent state and local opportunities block contains no records of active solicitations under this code. Without visibility into current or near-term demand signals, market activity under UNSPSC 51111901 cannot be characterized by issuing-body mix, geographic concentration, or representative opportunities at this time.